We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · May 06, 2021

Pembrolizumab vs Chemotherapy for PD-L1–High Metastatic NSCLC

Journal of Clinical Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50
J. Clin. Oncol 2021 Apr 19;[EPub Ahead of Print], M Reck, D Rodríguez-Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, M Gottfried, N Peled, A Tafreshi, S Cuffe, M O'Brien, S Rao, K Hotta, TA Leal, JW Riess, E Jensen, B Zhao, MC Pietanza, JR Brahmer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading